Dr. Matthias Magoola has been prominently featured in 256 Business News in a detailed article titled “Inside Africa’s Boldest Biotech Bet.” The feature dives into his ambitious $1.1 billion investment in Dei BioPharma, which is positioned to redefine pharmaceutical manufacturing in Africa. Located in Matugga, Uganda, the facility spans 300 acres and is designed to meet international production and research standards.
The article highlights Dr. Magoola’s inspiring journey—from growing up in poverty and battling malaria during university to becoming a leading force in pharmaceutical innovation. His early exposure to effective herbal treatments sparked a lifelong commitment to science and led to over 100 patent applications with the U.S. Patent and Trademark Office for treatments across cancer, Alzheimer’s, HIV, and more.
Dei BioPharma’s recent GMP certification by Uganda’s National Drug Authority marks a significant step forward, enabling commercial production to begin in 2025. The company’s pipeline includes groundbreaking developments such as guided RNA-based cancer therapies, a universal Foot and Mouth Disease vaccine, and experimental Alzheimer’s treatments designed to cross the blood-brain barrier.
With global partnerships, political support, and a vision centered on affordability and access, Dr. Magoola’s work is positioning Uganda as a biotech leader in the Global South. The article underscores how this project aims not only to serve Africa but to create high-impact medicines for underserved populations globally.
